Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.

Autor: Bixby B; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Vrba L; Precision Epigenomics, Tucson, AZ, USA., Lenka J; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Oshiro MM; Boyer Liver Institute, Department of Medicine, University of Arizona, Tucson, USA., Watts GS; Department of Pharmacology and Toxicology, University of Arizona, Tucson, USA., Hughes T; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Erickson H; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Chopra M; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Knepler JL; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, USA., Knox KS; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Phoenix, USA., Jarnagin L; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Phoenix, USA., Alalawi R; Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of Arizona, Phoenix, USA., Kala M; Department of Internal Medicine, University of Arizona, Phoenix, USA., Bernert R; Precision Epigenomics, Tucson, AZ, USA., Routh J; Midwestern University, Glendale, USA., Roe DJ; Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA., Garland LL; Hematology Oncology, Department of Medicine, University of Arizona, Tucson, USA., Futscher BW; Department of Pharmacology and Toxicology, University of Arizona, Tucson, USA., Nelson MA; Department of Pathology, University of Arizona, Tucson, AZ, 85724, USA. manelson@arizona.edu.

Publikováno v: Scientific reports [Sci Rep] 2024 Feb 05; Vol. 14 (1), pp. 2939. Date of Electronic Publication: 2024 Feb 05.

Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease.

Autor: Vrba L; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA., Futscher BW; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.; Precision Epigenomics Inc, Tucson, AZ, USA., Oshiro M; The University of Arizona Cancer Center, Tucson, AZ, USA., Watts GS; The University of Arizona Cancer Center, Tucson, AZ, USA.; Department of Medical Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA., Menashi E; Honor Health Hospital, Scottsdale, AZ, USA., Hu C; Dignity Health Chandler Regional Medical Center, Chandler, AZ, USA., Hammad H; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Pennington DR; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Golconda U; Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ, USA., Gavini H; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Roe DJ; The University of Arizona Cancer Center, Tucson, AZ, USA., Shroff RT; The University of Arizona Cancer Center, Tucson, AZ, USA.; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA., Nelson MA; The University of Arizona Cancer Center, Tucson, AZ, USA. mnelson@pathology.arizona.edu.; Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ, USA. mnelson@pathology.arizona.edu.; Precision Epigenomics Inc, Tucson, AZ, USA. mnelson@pathology.arizona.edu.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2022 Feb 22; Vol. 14 (1), pp. 28. Date of Electronic Publication: 2022 Feb 22.

Shenqifuzheng injection inhibits lactic acid-induced cisplatin resistance in NSCLC by affecting FBXO22/p53 axis through FOXO3.

Autor: Bo, Wei^1,2 (AUTHOR), Wang, Xiaokai² (AUTHOR), Yu, Ning¹ (AUTHOR), Wang, Chun¹ (AUTHOR) 1205055348@qq.com, Liu, Chunying¹ (AUTHOR) liuchunying6288@163.com

Publikováno v: Respiratory Research. 11/1/2024, Vol. 25 Issue 1, p1-15. 15p.

Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.

Autor: Bossio, Sabrina¹ (AUTHOR) sabrina.bossio@unicz.it, Urlandini, Lidia² (AUTHOR) lidiaurlandini@gmail.com, Perri, Anna¹ (AUTHOR) anna.perri@unicz.it, Conforti, Francesco³ (AUTHOR) francesco.conforti@unical.it, Aversa, Antonio¹ (AUTHOR), Di Agostino, Silvia⁴ (AUTHOR) sdiagostino@unicz.it, Rago, Vittoria² (AUTHOR) vittoria.rago@unical.it

Publikováno v: Life (2075-1729). Sep2024, Vol. 14 Issue 9, p1094. 14p.

DNA methylation changes in biomarker loci occur early in cancer progression.

Autor: Vrba L; The University of Arizona Cancer Center, The University of Arizona, Tucson, Arizona, 85724, USA., Futscher BW; The University of Arizona Cancer Center, The University of Arizona, Tucson, Arizona, 85724, USA.; Department of Pharmacology & Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona, 85724, USA.

Publikováno v: F1000Research [F1000Res] 2019 Dec 16; Vol. 8, pp. 2106. Date of Electronic Publication: 2019 Dec 16 (Print Publication: 2019).